Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | GNPAT | O15228 | 1/20 | 0.39 |
| ▸ | NPY1R | P25929 | 1/20 | 0.39 |
| ▸ | NPY2R | P49146 | 1/20 | 0.39 |
| ▸ | NPY4R | P50391 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 2/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.38 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.37 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31440712 | 0.87 | GNPAT (0.52) | GNPATRENCPB2OPRK1ERAP2 | |
| SCHEMBL29468820 | 0.84 | ABCB1 (0.42) | ABCB1MMP1 | |
| SCHEMBL30561190 | 0.83 | ITGB3 (0.52) | ITGB3ITGA2BGNPATCPB2ERAP2 | |
| SCHEMBL30422538 | 0.83 | CTSD (0.44) | ABCB1MMP1REN | |
| SCHEMBL30422599 | 0.83 | CTSD (0.44) | ABCB1MMP1REN | |
| SCHEMBL31510075 | 0.80 | NPY4R (0.46) | ABCB1MMP1NPY1RNPY2RNPY4R | |
| SCHEMBL30455293 | 0.80 | FOLH1 (0.41) | ITGB3ITGA2BGNPATCPB2ERAP2 | |
| SCHEMBL30483692 | 0.79 | MMP1 (0.47) | ABCB1MMP1NPY1RNPY2RNPY4R | |
| SCHEMBL30914236 | 0.79 | ERAP2 (0.42) | MMP1GNPATRENOPRK1ERAP2 | |
| SCHEMBL29631187 | 0.79 | ABCB1 (0.48) | ABCB1ITGB3ITGA2BMMP1REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125423-A1 | PEPTIDES FOR INCRETIN SYNTHESIS | LILLY CO ELI (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4598938-A2 | PEPTIDES FOR INCRETIN SYNTHESIS | Eli Lilly and Company (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2024077149-A2 | PEPTIDES FOR INCRETIN SYNTHESIS | ELI LILLY AND COMPANY (US) | 2024-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125423-A1 | PEPTIDES FOR INCRETIN SYNTHESIS | IAPP, GLP1R, VIP | ABCB1 2654/4885ITGB3 3295/4885ITGA2B 4167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.